Related Experiment Videos
High-dose dexamethasone for refractory or relapsing multiple myeloma
W R Friedenberg1, R A Kyle, W H Knospe
1Department of Hematology, Marshfield Clinic, Wisconsin 54449.
American Journal of Hematology
|March 1, 1991
Summary
High-dose dexamethasone monotherapy showed a 40% objective response rate in advanced cancer patients but caused significant toxicity. Maintenance therapy was well-tolerated, though further study is needed for remission induction efficacy.
Area of Science:
- Oncology
- Pharmacology
Background:
- The VAD regimen (Vincristine, Adriamycin, Dexamethasone) is a standard treatment.
- Assessing dexamethasone as a single agent is crucial for treatment optimization.
Purpose of the Study:
- To evaluate the efficacy and toxicity of single-agent dexamethasone in advanced cancer.
- To determine response rates, survival, and side effects of this monotherapy.
Main Methods:
- An ECOG pilot study administered 40 mg oral dexamethasone daily for 4 days weekly for 8 weeks.
- Patients achieving response were maintained on treatment every 2 weeks.
- Efficacy and toxicity were assessed in evaluable patients.
Main Results:
- 13/32 (40%) patients achieved objective responses; 8/28 (28.5%) had subjective responses.
- 55% of patients experienced moderate to severe toxicity, including CNS effects, GI bleeding, and infections.
- Median survival was 19 weeks (31 weeks for responders, 9 weeks for non-responders).
Conclusions:
- High-dose dexamethasone monotherapy yields significant partial responses but is linked to excessive toxicity.
- Maintenance therapy with less frequent dexamethasone administration was tolerated.
- Further research is needed to establish the efficacy of dexamethasone monotherapy for remission induction.